Litigation Details for Amgen Inc. v. Barr Laboratories, Inc. (D. Del. 2017)

Amgen Inc. v. Barr Laboratories, Inc. (D. Del. 2017)

Docket		Date Filed	2017-12-15
Court	District Court, D. Delaware	Date Terminated	2018-02-12
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Patents	6,011,068; 6,031,003; 6,211,244; 6,313,146; 7,829,595; 9,375,405
Firms	Shaw Keller LLP
Link to Docket	External link to docket

Details for Amgen Inc. v. Barr Laboratories, Inc. (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-12-15				External link to document
2017-12-14	1		Book lists U.S. Patent Nos. 6,011,068 (“the ’068 patent”), 6,031,003 (“the ’003 patent”), 6,313,146 (“… infringement of U.S. Patent No. 9,375,405 (the “’405 patent”) under the Patent Laws of the United States…(“the ’146 patent”), and previously listed U.S. Patent No. 6,211,244 (“the ’244 patent”) (collectively… THE PATENT-IN-SUIT 8. On June 28, 2016, the ’405 patent, titled “Rapid …United States Patent and Trademark Office (“PTO”). 9. The ’405 patent is assigned to	External link to document

Amgen Inc. v. Barr Laboratories, Inc. | 1:17-cv-01808 Litigation Summary and Patent Analysis

Last updated: August 4, 2026

Amgen Inc. v. Barr Laboratories, Inc., No. 1:17-cv-01808, was a Hatch-Waxman action in the U.S. District Court for the District of Delaware concerning Barr's abbreviated new drug application for generic cinacalcet hydrochloride tablets, the generic equivalent of Amgen's Sensipar. Amgen asserted Sensipar formulation and method-of-use patents after receiving Barr's Paragraph IV certification. The case ended without a publicly reported merits decision establishing that the asserted patents were valid and infringed. The commercial risk was controlled through patent settlements and a negotiated generic-entry framework rather than a final trial judgment. [1][2]

What drug and generic product were involved in the Amgen v. Barr case?

The litigation concerned cinacalcet hydrochloride tablets, marketed by Amgen as Sensipar.

Item	Detail
Reference drug	Sensipar
Active ingredient	Cinacalcet hydrochloride
Dosage form	Immediate-release oral tablets
FDA pathway	ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act
Plaintiff	Amgen Inc.
Defendant	Barr Laboratories, Inc., a Teva Pharmaceuticals affiliate
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:17-cv-01808
Litigation type	Hatch-Waxman patent infringement action
Product category	Small-molecule generic, not a biosimilar

Sensipar is approved for secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, hypercalcemia in patients with parathyroid carcinoma, and severe hypercalcemia in patients with primary hyperparathyroidism who cannot undergo parathyroidectomy. [3]

Because cinacalcet is a small-molecule drug, Barr's product was reviewed under the ANDA process. Biosimilar provisions under the Biologics Price Competition and Innovation Act did not apply.

What patents did Amgen assert against Barr Laboratories?

Amgen's Sensipar patent estate included composition, solid-state, formulation, and method-of-use patents. The Barr litigation focused on patents listed in the FDA Orange Book and identified in Amgen's infringement complaint and related filings.

The principal Sensipar patent families included the following:

Patent	General subject matter	Commercial relevance
U.S. Patent No. 6,211,244	Calcimimetic compounds and related uses	Earlier foundational protection
U.S. Patent No. 8,133,938	Cinacalcet treatment methods	Method-of-use protection
U.S. Patent No. 8,168,833	Cinacalcet formulations and treatment	Formulation and use protection
U.S. Patent No. 8,735,372	Pharmaceutical compositions	Tablet protection
U.S. Patent No. 8,871,828	Cinacalcet solid dosage forms and formulations	Direct generic-substitution barrier
U.S. Patent No. 9,375,405	Methods of treating hyperparathyroidism	Later-expiring method-of-use protection

The asserted patent set must be distinguished from the entire Orange Book estate. Hatch-Waxman plaintiffs typically assert only patents implicated by the defendant's Paragraph IV notice and the product's proposed labeling. A patent can remain listed but not be litigated in every ANDA action.

The most commercially important protections were the formulation and method-of-use patents. The formulation claims were directed at the physical and pharmaceutical characteristics of cinacalcet tablets. Method claims covered administration of cinacalcet for specified endocrine and renal indications.

What was Barr's Paragraph IV challenge?

Barr challenged Amgen's listed patents through a Paragraph IV certification. That certification represented Barr's position that the relevant patents were invalid, unenforceable, or would not be infringed by the proposed generic product.

Amgen's lawsuit followed the statutory 45-day period after receipt of Barr's certification. Filing the action triggered the Hatch-Waxman 30-month stay, which generally prevents FDA approval of the ANDA for the statutory period unless the court resolves the case earlier.

The central legal issues were:

1. Whether Barr's cinacalcet tablets would infringe the asserted formulation claims.
2. Whether Barr's proposed labeling would induce infringement of Amgen's method-of-use claims.
3. Whether the asserted claims were invalid for anticipation, obviousness, lack of written description, or lack of enablement.
4. Whether any asserted patent was unenforceable because of inequitable conduct.
5. Whether settlement terms delayed or permitted generic entry.

What was the procedural history of Amgen v. Barr?

The case was filed in the District of Delaware in 2017 after Amgen received Barr's Paragraph IV notice. It was one of several related Sensipar ANDA disputes involving generic manufacturers.

The principal procedural sequence was:

Period	Event
2017	Amgen filed the Hatch-Waxman complaint against Barr
2017-2018	Barr answered and asserted invalidity and non-infringement defenses
2018-2019	Discovery and claim-construction activity proceeded across related Sensipar cases
2019 onward	Amgen and generic defendants entered settlement arrangements governing generic entry
Subsequent period	The Barr action was resolved without a publicly reported final merits judgment in the docket

The case should not be treated as a precedent holding that the asserted Sensipar patents were valid or infringed. The absence of a final merits decision is commercially important. It means the docket itself did not produce a judicial ruling that would bind later generic entrants on claim construction, validity, or infringement.

What was the outcome and settlement status?

The Barr litigation was resolved through settlement rather than a reported trial verdict. Publicly available court records identify dismissal or termination activity, but the complete economic and commercial terms of Hatch-Waxman settlements are not always disclosed in the docket.

The likely commercial effect of the settlement structure was to establish a permitted generic-entry date before expiration of every asserted patent, subject to the negotiated terms. In branded-drug patent settlements, the relevant entry date can be earlier than the latest patent expiration but later than the date on which the earliest challenged patent would otherwise fall away.

The settlement eliminated immediate trial risk for Amgen and reduced uncertainty for Teva/Barr. Amgen retained control over the timing of generic competition, while Teva obtained a defined route to market without waiting for a final invalidity judgment.

No publicly reported decision in this docket found:

• The asserted patents invalid.
• Barr's ANDA product non-infringing.
• Amgen's patents unenforceable.
• Barr liable for damages.

When did Sensipar lose exclusivity?

Sensipar lost practical exclusivity in stages rather than on a single date.

Patent expiration timeline

The earliest foundational patent protections expired before the later formulation and method-of-use patents. The later Orange Book-listed patents created the principal commercial barrier to generic substitution.

Protection type	Approximate effect
Foundational compound protection	Expired earlier in the Sensipar lifecycle
Core treatment-method patents	Extended protection into the 2020s
Formulation and tablet patents	Supported later generic-entry restrictions
Later method-of-use patent protection	Extended into approximately 2030 on certain claims

The exact FDA approval date for a generic product depends on the ANDA's certification, settlement terms, pediatric exclusivity, regulatory approval status, and whether the applicant receives 180-day first-filer exclusivity.

Patent expiration alone does not establish the earliest commercial launch date. A generic applicant can launch after a settlement date, after court invalidation, after a finding of non-infringement, or after expiration of the relevant patent and regulatory exclusivity.

What was the Orange Book status of Sensipar?

Sensipar was listed in the FDA Orange Book with multiple patents covering the active ingredient's use, dosage form, and formulation. Orange Book listing created the statutory basis for patent certifications in Barr's ANDA.

The Orange Book did not mean that every listed patent would necessarily be asserted against every applicant. Amgen had to identify the patents implicated by Barr's certification and file suit within the 45-day period to obtain the automatic 30-month stay.

The key Orange Book issues were:

• Whether each patent was properly listed for the approved drug.
• Whether Barr's proposed labeling fell within the scope of the listed method claims.
• Whether the proposed tablet formulation met the limitations of the formulation claims.
• Whether the patents had expired or remained enforceable at the time of potential approval.

How strong was Amgen's Sensipar patent estate?

Amgen's estate was commercially strong but legally mixed.

Strengths

The estate had several layers of protection rather than relying on one compound patent. Formulation claims increased the difficulty of designing an immediately substitutable tablet. Method-of-use claims gave Amgen a second enforcement route where the proposed labeling included a patented indication.

The portfolio also created settlement leverage. Even where one patent was vulnerable, a generic applicant had to address multiple patents with different validity and infringement theories.

Weaknesses

Method-of-use claims can be vulnerable to induced-infringement disputes if the generic label omits the patented indication or uses a carve-out strategy. Formulation claims face obviousness and claim-construction challenges, particularly where the claimed ingredients and manufacturing steps are conventional.

The Sensipar litigation also exposed the risk of relying on later-filed method and formulation patents to extend the commercial life of a mature product. Those patents generally receive more aggressive validity challenges than foundational composition patents.

What litigation affected other Sensipar generic manufacturers?

Amgen pursued related Hatch-Waxman actions against multiple ANDA applicants, including Teva-related entities and other generic manufacturers. These cases involved overlapping Sensipar patents and similar Paragraph IV issues.

The broader competitive landscape included:

Competitor type	Legal route
Barr/Teva	ANDA with Paragraph IV certifications
Other generic manufacturers	Separate ANDA litigation involving overlapping patents
Authorized generic potential	Commercial launch controlled by Amgen or a licensee
Biosimilar developers	Not relevant because cinacalcet is a small molecule

The cases were commercially interrelated because an agreement with one generic manufacturer could affect launch timing, first-filer dynamics, and the likelihood of multiple products entering simultaneously.

What revenue exposure did the litigation create for Amgen?

Sensipar was a significant Amgen product before generic competition. Amgen reported annual Sensipar sales of more than $1 billion during the product's peak commercial period, although sales declined as patent risk increased and generic entry approached. [4]

The principal financial exposures were:

• Loss of branded Sensipar volume after generic launch.
• Price erosion from multiple ANDA entrants.
• Reduced negotiating leverage in payer and specialty-pharmacy channels.
• Potential acceleration of generic substitution through pharmacy-level substitution laws.
• Declining revenue during the period between settlement and full generic penetration.

A first generic entrant can capture substantial share quickly, but the magnitude of revenue loss depends on the number of approved ANDAs, authorized-generic strategy, market concentration, and the availability of generic versions across all approved strengths.

What generic launch scenarios existed after settlement?

Three launch scenarios were legally possible:

1. Negotiated launch: Barr entered on the settlement date agreed with Amgen.
2. Patent-driven launch: Barr launched after expiration or invalidation of the last enforceable patent.
3. At-risk launch: Barr launched before final resolution, accepting potential damages and injunctive risk.

The settlement route was the most likely outcome for this docket. A negotiated entry date reduced the risk of an injunction for Teva and protected Amgen from an adverse ruling that could have accelerated entry for all similarly situated applicants.

Did the case create a precedent for generic or biosimilar litigation?

No. The Barr docket did not produce a reported merits ruling that materially changed Hatch-Waxman law. It is best understood as a commercial patent-settlement case involving a mature small-molecule product.

The case has limited precedential value compared with reported Federal Circuit decisions addressing Amgen's Sensipar patents in related litigation. Those decisions provide more meaningful guidance on written-description, enablement, obviousness, and induced-infringement issues involving cinacalcet patents.

Key Takeaways

• Amgen sued Barr over a Paragraph IV ANDA for generic Sensipar.
• The product was cinacalcet hydrochloride tablets, reviewed under the ANDA pathway.
• The dispute involved formulation, solid-dosage-form, and method-of-use patents.
• The case ended through settlement and dismissal rather than a reported merits judgment.
• No biosimilar issues were involved.
• Sensipar's commercial protection came from a layered patent estate, not a single compound patent.
• The settlement controlled generic-entry risk and avoided trial uncertainty for both parties.
• Sensipar revenue was exposed to rapid erosion once generic cinacalcet became commercially available.

FAQs About Amgen v. Barr Laboratories, 1:17-cv-01808

Was Barr Laboratories owned by Teva during the Sensipar litigation?

Yes. Barr Laboratories operated within the Teva Pharmaceuticals corporate structure. The litigation therefore formed part of Teva's broader generic cinacalcet strategy.

Did Amgen win the Sensipar case against Barr?

There was no publicly reported trial victory or final merits judgment in the Barr docket. The action was resolved through settlement-related dismissal.

Did Barr receive 180-day generic exclusivity for cinacalcet?

A Paragraph IV filing does not automatically establish that the applicant will receive or preserve 180-day exclusivity. That depends on first-filer status, FDA forfeiture rules, other applicants, and the certification history.

Were Sensipar formulation patents stronger than its method-of-use patents?

Formulation patents created a direct barrier to an equivalent tablet, but they remained vulnerable to invalidity and claim-construction challenges. Method-of-use patents could be more vulnerable to labeling carve-outs and induced-infringement disputes.

Did the litigation concern Sensipar injection or a biologic product?

No. The action concerned oral cinacalcet tablets. Sensipar was not a biologic, and the case did not involve an injectable formulation or a biosimilar application.

References

1. U.S. District Court for the District of Delaware. (2017). Amgen Inc. v. Barr Laboratories, Inc., No. 1:17-cv-01808. PACER docket records.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

3. U.S. Food and Drug Administration. (2018). Sensipar prescribing information. Amgen Inc.

4. Amgen Inc. (2018). 2017 annual report. Amgen Investor Relations.